Insulin brand given the all-clear

THE PHARMACEUTICAL Services of Cyprus have announced that they will not be ordering the discontinuation of the usage of the Insulin Glargine, following the conclusion of a European Medicines Agency investigation into possible links between the insulin analogues and cancer.

The insulin, which is sold in the EU under the names of Lantus and Optisulin, had been the subject of four medical studies which suggested that there might be a possible link between the two medicines and cancer, particularly breast cancer.

According to a press release filed on its website on July 23, “The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that the available data does not provide a cause for concern and that changes to the prescribing advice are therefore not necessary.”

Cyprus’ Pharmaceutical Services had announced at the beginning of July that they had been informed by the EMEA of their pending investigation into the safety of the insulin, however had not ordered a cessation of its use until the EMEA concluded its investigations. Its safety has now been assured, however the EMEA also announced that because of the lack of conclusive evidence, it “has requested the marketing authorisation holder, Sanofi-Aventis, to develop a strategy for generation of further research in this area.”

It also stated that it was “exploring possibilities for cooperation with academia to generate further information.”

Unless more substantial evidence does arise suggesting a detrimental effect of the drug, patients have been assured that they should feel safe continuing its usage.